Drugs / WEF-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07148128 | Jul 2025 → Jan 2028 expected | colorectal cancer, lung cancer | Auricula Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WEF-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07148128 ↗ |
| Route | Intravenous | “Starting dose of 0.3 mg/m2 q4wks IV, dose escalation” NCT07148128 ↗ |